Patent 10414752 was granted and assigned to FORMA Therapeutics on September, 2019 by the United States Patent and Trademark Office.
The application relates to an inhibitor of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula (I-13):